Canada: IP And Competition: The Competition Act Applies To Assignment Of Patents

On 2 November 2005, a unanimous Federal Court of Appeal (the FCA) gave an important decision in Apotex Inc v Eli Lilly and Co concerning the interplay between competition law and intellectual property rights in Canada. The principal issue addressed by the FCA was whether the assignment of a patent could constitute an agreement or arrangement to lessen competition unduly, contrary to section 45 of the Competition Act. The FCA held that the assignment of a patent may, as a matter of law, result in an undue lessening of competition, notwithstanding that this assignment is otherwise authorised and lawful under Canada’s patent legislation.

History of proceedings

As described previously in CLI 12 July 2005 (p12), the FCA’s decision has its roots in a long-standing patent infringement dispute between Eli Lilly and Apotex concerning the manufacture of the antibiotic cefaclor. In 1997, Eli Lilly commenced an action against Apotex, alleging that it had infringed eight of its manufacturing process patents, four of which had been assigned to Eli Lilly by Shionogi in 1995. In 2001, Apotex amended its statement of defence and counterclaim to argue that the assignment of these patents constituted an unlawful agreement, contrary to section 45 of the Competition Act, thereby entitling Apotex to damages under section 36 of the Act. Interestingly, the process patents in question had expired in 2000 and the patent for cefaclor had expired in 1995.

Once Apotex had initiated its counterclaim, a series of motions for summary judgment was brought by Eli Lilly and Shionogi regarding the potential application of section 45. These motions wound their way through the Federal Court and then the FCA through various appeals. Initially, Justice Hugessen, a judge of the Federal Court Trial Division, held that Apotex’s conspiracy counterclaim should be dismissed. Apotex’s appeal of this decision was allowed by the FCA and the matter was remanded back to Justice Hugessen for further consideration. Justice Hugessen refused to depart from his original reasoning, however, and struck the counterclaim in a second decision. Apotex appealed once more to the FCA which, in its 2 November judgment, held that Justice Hugessen had erred in law and that Apotex’s counterclaim should proceed.

Of special note is the fact that the Competition Bureau applied for and was granted leave to intervene in these proceedings. In its application for leave, the Bureau argued that Justice Hugessen’s decision would cause "great mischief " if upheld and lacked support in legal precedent and public policy as well. In its decision to grant the Bureau’s application for leave, the FCA held that the Bureau had standing because its ability to administer the Competition Act in respect of patent rights could be affected by the outcome of the case. In particular, the Bureau would be able to provide the FCA with its input regarding Justice Hugessen’s assertion that his decision was consistent with the Bureau’s intellectual property enforcement guidelines (IPEGs). In its materials, the Bureau disagreed with this view.

The FCA’s decision

Throughout the proceedings, Eli Lilly and Shionogi had argued that section 45 could not apply as a matter of law to an assignment of patent rights because the Canadian Patent Act specifically authorises holders of patents to assign such rights. The argument was that an assignment of rights made lawful by the Patent Act is incapable, by definition, of being unlawful under the Competition Act, even if it lessens competition. Eli Lilly and Shionogi relied on a 1991 decision of the FCA in Molnlycke AB v Novopharm Kimberly-Clarke of Canada Ltd as authority for this proposition, which was accepted by Justice Hugessen in his decision dismissing Apotex’s counterclaim.

The FCA disagreed with Justice Hugessen and held that Molnlycke applies only when the market power created by the assignment is inherent in the patent assigned – ie where the assignment of the patent in and of itself increases or creates market power in a relevant market. However, when there are other factors which contribute to the creation or increase of market power, then Molnlycke will not preclude the application of section 45. The FCA distinguished Molnlycke from the case at bar on the basis that it was the combination of the 1995 assignment from Shionogi, together with Eli Lilly’s already existing ownership of patents for the other commercially viable methods of production for cefaclor, which had led to a lessening of competition and potentially invoked the application of section 45.

In reaching its decision, the FCA also noted that section 45 does not contain any express exception for the exercise of patent rights, in contrast to other provisions of the Competition Act which contain such an exemption. In addition, the FCA held that "an interpretation of [the Patent Act] which does not immunise the assignment of patents from section 45 when it lessens competition is consistent with the purpose of the Competition Act" which, as stated in section 1.1, is to "maintain and encourage" competition. Furthermore, the FCA found that this interpretation of the Patent Act was more consistent with the enforcement approach set out in the Competition Bureau’s IPEGs.

The alternative argument offered by Eli Lilly and Shionogi was that, even if section 45 could apply in theory, it did not apply in practice because on the facts of the case the assignment did not lessen competition unduly. The FCA dismissed this argument on the basis that even Justice Hugessen had found that, on the facts, there had been at least a lessening of competition in the relevant market. The FCA stated that the question of whether this lessening of competition was "undue" should be decided at trial.

The FCA also left to trial the particular issues of whether (1) Apotex’s claims were in fact statute-barred because they were beyond the limitation period set out in section 36 of the Competition Act, and (2) Apotex had sustained any actual damages, another pre-condition for a claim under section 36. With respect to the relevant limitation period, it is notable that even though the assignment took place in 1995, the FCA characterised the conduct as ongoing "as long as the assignment had competition-lessening effect". Although the FCA’s comments on this point are obiter, this approach differs from the judicial treatment of limitation periods in respect of mergers or other analogous events which are typically viewed as complete once implemented.


Overall, the FCA’s decision that the Patent Act cannot in all circumstances oust the application of the Competition Act is hardly a new or surprising position. This general proposition is consistent with the Bureau’s IPEGs and with other international jurisprudence regarding the interplay between competition law and intellectual property rights. That said, the FCA’s decision is notable in that it underscores the careful consideration which must be afforded to competition law issues when licences or patents are assigned. As demonstrated in this case, the assignment of a patent right could land the parties in the middle of an alleged criminal conspiracy, raising the prospect of prosecution and follow-on civil actions.


The FCA’s decision is available from the Federal Court of Appeal’s website at:

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Mark C. Katz
In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions